Manufacturing roundup: Aceto rebrands to Actylis; WuXi STA opens another facility
A New York-based manufacturer has rebranded after netting several acquisitions in the past few years.
Aceto, a manufacturer of ingredients and raw materials, has rebranded to Actylis. The move will bring all 10 acquisitions the company has made in the past several years under one banner.
“Actylis unites multiple industry specialists with a wide range of capabilities into a new, global enterprise with a unique hybrid approach that is greater than the sum of its parts. This consolidation enables us to offer customers across diverse locations and industries highly flexible, customized solutions addressing their specific needs while assuring reliable on-time delivery of the high-quality ingredients essential to their success,” said CEO Gilles Cottier in a statement.
With all the companies now under one name, the company now boasts a headcount of over 850 staff with a presence in 10 countries.
The company acquired Irish company A&C Bio Buffer last year to help bolster its Covid-19 relief efforts and expand its manufacturing capabilities.
WuXi STA continues its expansion drive with the opening of an oral drug manufacturing site
WuXi STA is keeping up its momentum by opening another site in its manufacturing chain.
The company announced it has opened its high potency oral drug product manufacturing site at its campus in Wuxi, China. According to the company, this move allows it to manufacture high-potency drug candidates as well as build out its capacity for more drug production.
The facility can cover a wide range of services including wet and dry granulation, tablet compression and coating and capsule filling. WuXi STA expects the facility to manufacture 400 million tables and 200 million capsules annually.
The facility will also allow it to provide a network for R&D services and manufacturing of high potency active pharmaceutical ingredients into commercial products. The company is also planning to open another high potency parental production plant at the WuXi campus in Q3 of next year.
“As our global partners and customers seek accelerated pathways for new drug development, WuXi STA is committed to further enhancing our integrated platform to enable more healthcare breakthroughs that benefit patients worldwide,” said WuXi STA CEO Mingzhang Chen, in a statement.
WuXi STA’s recent expansion projects include the building of a 190-acre manufacturing campus in Middletown, DE, along with the opening of several other production facilities in China.
Chinese CDMO plans for a building project in Jiangsu Province
Asymchem, a CDMO that has a presence on three continents, is looking much closer to home for its next project.
According to a document submitted to the Hong Kong Stock Exchange, Asymchem it is planning to construct a site at the Jiangsu Taixing Economic Development Zone, a development area along the banks of the Yangtze River outside of Shanghai.
The site will eventually house R&D operations as well as the manufacturing of chemicals and small molecule drug products. The total investment that is planned for the site is planned to be within the range of RMB4,000,000,000 to RMB5,000,000,000 ($559.8 million to $669.77 million).
Asymchem plans to fund the project with its cash or by “self-raising funds”, but no details have been released. Details on size, employee count, or when construction will start have also not been released.
Nucleus Biologics pulls back the curtain on new San Diego cell culture manufacturing site
A San Diego cell culture producer has opened a new facility.
Nucleus Biologics, a provider of cell culture media products, has cut the ribbon on its newest facility. The company’s new 19,884-square-foot facility has two powder and four liquid cleanrooms to boost cell culture manufacturing.
Nucleus said that it can increase its production to 2.5 million liters of product per year.
“We have seen rapid growth in both the cell and gene therapy industry and our business and are expanding manufacturing and cleanroom capacity to support our therapy customers to speed the time from discovery to cure,” said David Sheehan CEO of Nucleus Biologics, in a statement.
The move is one of the latest for the company as it has expanded to 70 staff members and has netted deals with Cytiva and with one of its spinoffs Stoic Bio.